Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis pleased with Multaq recommendation

Sanofi-Aventis pleased with Multaq recommendation

19th March 2009

Sanofi-Aventis is pleased with the positive outcome of its drug Multaq, it has asserted.

In previous studies, the treatment was proved to be the only anti-arrhythmic medication to significantly reduce morbidity and mortality in patients with atrial fibrillation or flutter.

The investigations have also shown it is effective in aiding those with a recent history of these conditions. Around 4.5 million people in the European Union suffer from a form of the condition and it is becoming a public health concern for the aging population, according to Sanofi-Aventis.

The Cardiovascular and Renal Drug Advisory Committee voted ten to three in favour for the approval of the medication by the Food and Drug Administration (FDA).

Although the latter is not bound by the former’s decision, it is likely to take the commendation into account.

Jean-Pierre Lehner, chief medical officer of the Sanofi-Aventis, commented: “The panel’s insightful feedback, which concluded with a positive vote, is an important step in gaining FDA approval of Multaq.”

Earlier this month, the pharmaceutical company announced that it now holds 98.6 peer cent of Zentiva’s share capital.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.